Evogene Ltd.

Equities

EVGN

IL0011050551

Biotechnology & Medical Research

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 07:54:13 16/05/2024 pm IST			5-day change	1st Jan Change
249.1 ^ILa	-3.86%		-6.35%	-16.91%

02/04	Evogene Ltd. and The Kitchen FoodTech Hub Establishes Finally Foods Ltd	CI
20/03	Evogene Receives Minimum Bid Price Non-Compliance Notice From Nasdaq	MT

Evogene Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022

March 09, 2023 at 05:30 pm IST

Evogene Ltd. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was USD 1.68 million compared to USD 0.93 million a year ago. Net loss was USD 26.64 million compared to USD 27.79 million a year ago.

Basic loss per share from continuing operations was USD 0.65 compared to USD 0.69 a year ago.

Latest news about Evogene Ltd.

Evogene Ltd. and The Kitchen FoodTech Hub Establishes Finally Foods Ltd	02/04	CI
Evogene Receives Minimum Bid Price Non-Compliance Notice From Nasdaq	20/03	MT
Transcript : Evogene Ltd., Q4 2023 Earnings Call, Mar 07, 2024	07/03
Evogene Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03	CI
Evogene Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03	CI
Evogene Unit, Corteva Agriscience Identify New Potential Class of Herbicidal Molecules	06/03	MT
AgPlenus Achieves Milestone in Collaboration with Corteva to Develop Novel Herbicides	06/03	CI
Casterra Announces New Agreements with Subsidiary of Evogen Ltd., to Meet Growing Demand for Its Elite Castor Seed Varieties	05/03	CI
Evogene Files $200 Million Mixed Shelf	01/03	MT
Evogene Ltd. and Verb Biotics LLC Enters into Collaboration Agreement	06/02	CI
Casterra Ag Ltd., a subsidiary of Evogene Ltd Announces Executive Changes, Effective January 1, 2024	19/12	CI
Transcript : Evogene Ltd., Q3 2023 Earnings Call, Nov 15, 2023	15/11
Earnings Flash (EVGN) EVOGENE Posts Q3 Revenue $3.8M	15/11	MT
Evogene Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
Colors Farm Ltd, Evogene Ltd. and Ben-Gurion University Collaborate to Establish Crustacean Gene Editing Technology	31/23/31	CI
Alliance Global Starts Evogene at Buy With $1.85 Price Target	02/23/02	MT
Lake Street Adjusts Evogene's Price Target to $3 From $2, Keeps Buy Rating	18/23/18	MT
Transcript : Evogene Ltd., Q2 2023 Earnings Call, Aug 17, 2023	17/23/17
Earnings Flash (EVGN) EVOGENE Posts Q2 Revenue $654,000	17/23/17	MT
Evogene Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	17/23/17	CI
Evogene Ltd 's ChemPass AI Tech-Engine is Introduces with New Breakthrough Machine Learning Technology for Target-Protein Discovery	25/23/25	CI
Biomica Ltd. Reports Interim Positive Results from Pre-Clinical Studies in its IBS Program	19/23/19	CI
Evogene Expects to Raise $8.5 Million in Gross Proceeds From Registered Direct Offering; Shares Fall	17/23/17	MT
Evogene's Lavie Bio Says Corteva to Develop, Commercialize Lead Fungicide Product Candidates	17/23/17	MT
Evogene Subsidiary Receives Additional $2.2 Million in Purchase Orders for Castor Seeds	03/23/03	MT

Chart Evogene Ltd.

Duration

Period

More charts

Company Profile

Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Sector

Biotechnology & Medical Research

Calendar

23/05/2024 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EVOGENE LTD.	-16.91%	34.13M
MODERNA, INC.	+34.44%	50.85B
IQVIA HOLDINGS INC.	+0.65%	42.82B
LONZA GROUP AG	+49.62%	42.03B
CELLTRION, INC.	-4.96%	29.55B
ICON PUBLIC LIMITED COMPANY	+10.95%	26.11B
ALNYLAM PHARMACEUTICALS, INC.	-21.65%	19.13B
BIO-TECHNE CORPORATION	+8.77%	13.05B
MEDPACE HOLDINGS, INC.	+27.51%	12.16B
UNITED THERAPEUTICS CORPORATION	+24.54%	12.08B

Other Biotechnology & Medical Research